BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• Press Releases

  Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

  December 29, 2024

   · 

  4 min read
• Press Releases

  TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

  December 29, 2024

   · 

  19 min read
• Press Releases

  Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

  December 29, 2024

   · 

  11 min read
• Press Releases

  Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

  December 29, 2024

   · 

  13 min read
• Press Releases

  U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

  December 29, 2024

   · 

  19 min read
• Press Releases

  CEL-SCI Announces Pricing of $5 Million Public Offering

  December 29, 2024

   · 

  4 min read
• Press Releases

  Vor Bio Announces $55.6 Million Private Placement

  December 29, 2024

   · 

  6 min read
• Press Releases

  Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

  December 29, 2024

   · 

  10 min read
• Press Releases

  180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

  December 29, 2024

   · 

  9 min read
• Press Releases

  YolTech Therapeutics Granted FDA Orphan Drug and Rare Pediatric Disease Designations for YOLT-203 to Treat Primary Hyperoxaluria Type 1

  December 29, 2024

   · 

  3 min read